{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '8.7.', 'Pharmacogenetics', 'Single nucleotide polymorphisms may be analyzed as part of an exploratory PGx analysis, which', 'may be performed on biosamples from subjects who have consented for this assessment and', 'where permitted by local law. Subject confidentiality will be maintained, except under subpoena', 'from regulatory and/or law enforcement agencies.', 'Samples may be collected from all subjects, except those who opt out and where impermissible', 'by law and local authorities.', 'See Appendix 5 (Section 10.5) for information regarding genetic research. Details on processes', 'for collection and shipment and destruction of these samples can be found in the Laboratory', 'Manual.', '9.', 'STATISTICAL CONSIDERATIONS', '9.1.', 'Statistical Hypotheses', 'This study aims to demonstrate the superiority of GB001 versus placebo, when added to SOC', 'therapy, on change from baseline to Week 16 in SNOT-22 score in the overall population and on', 'change from baseline to Week 16 in NPS in the CRSwNP stratum.', '9.2.', 'Sample Size Determination', 'A total sample size of approximately 100 subjects overall (approximately 50 per treatment group,', 'randomized in a 1:1 ratio) is estimated to provide approximately 90% power to detect a treatment', 'difference of 12.0 between GB001 and placebo at a 0.050 two-sided level of significance for the', 'primary endpoint of change from baseline to Week 16 in SNOT-22 score, assuming a common', 'standard deviation of 16.8 and a dropout rate of 15% using a two-sided t-test.', 'A total sample size of approximately 64 subjects in the CRSwNP stratum (approximately 32', 'per treatment group, randomized in a 1:1 ratio) is estimated to provide approximately 80% power', 'to detect a treatment difference of 1.3 between GB001 and placebo at a 0.050 two-sided level of', 'significance for the secondary endpoint of change from baseline to Week 16 in NPS, assuming', 'a common standard deviation of 1.7 and a dropout rate of 15% using a two-sided t-test.', 'Therefore, the total sample size of approximately 100 subjects overall will consist of', 'approximately 64 subjects in the CRSwNP stratum and 36 subjects in the CRSsNP stratum.', '9.3.', 'Populations for Analyses', 'The following major analysis populations are defined:', 'All enrolled population: All subjects who consent to study participation.', 'This population will be used for summary of subject disposition.', 'Run-in period population: All enrolled subjects who enter the Run-in period.', 'This population will be used for summary of subject disposition.', '46', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Intent-to-treat (ITT) population: All subjects who are randomized and receive', 'at least one dose of IP, with subjects grouped according to randomized treatment.', 'This population will be used for all efficacy analyses.', 'Safety population: All subjects who receive at least 1 dose of IP, with subjects', 'grouped according to their actual treatment. This population will be used for safety', 'analyses.', '9.4.', 'Statistical Analyses', 'In general, continuous variables will be summarized using the number of subjects with', 'non-missing data, mean, standard deviation, minimum, and maximum. Continuous variable', 'summaries will include standard error, where appropriate. Categorical variables will be', 'summarized using counts and percentages. Baseline value will be defined as the last non-missing', 'value on or before the date of the first dose of IP.', 'Analyses will generally be performed for the overall population and by stratum (CRSwNP', 'and CRSsNP), other than endpoints associated with outcomes that are specific to the CRSwNP', 'stratum (eg, NPS).', 'All statistical hypothesis testing will be at an 0.050 two-sided level of significance.', '9.4.1.', 'Efficacy Analyses', '9.4.1.1.', 'Primary Efficacy Analysis', 'The primary endpoint of change from baseline to Week 16 in SNOT-22 score will be', 'analyzed by a mixed-effects model with repeated measures (MMRM) using a restricted', 'maximum-likelihood (REML)-based approach. The MMRM model will include change from', 'baseline scores up to Week 16 as the response variable; the fixed, categorical effects of treatment', 'group, randomization strata defined by the presence or absence of NP and comorbid asthma', '(ie, CRSwNP with comorbid asthma, CRSwNP without comorbid asthma, and CRSsNP),', 'country, visit, and treatment group by visit interaction; and the continuous, fixed covariates of', 'baseline SNOT-22 score and baseline SNOT-22 score by visit interaction. An unstructured', 'covariance structure will be used to model within-subject error. If this analysis fails to converge,', 'a compound symmetric or first-order autoregressive covariance structure will be utilized for the', 'primary analysis, based on the covariance structure converging to better fit as determined based', \"on Akaike's information criterion.\", 'Statistical inference for treatment group comparison of GB001 40 mg versus placebo at Week 16', 'will be derived from the above MMRM model, with results presented in terms of a least squares', 'mean difference, along with the corresponding 95% confidence interval (CI) and p-value.', '9.4.1.2.', 'Secondary Efficacy Analysis', 'The secondary endpoints of change from baseline to Week 16 in Lund-Mackay total score and in', 'UPSIT score will be analyzed utilizing analysis of covariance (ANCOVA) models including', 'covariates for baseline score, presence or absence of bilateral NP, and treatment group. Results', 'will be presented in terms of least squares mean differences, along with corresponding 95% CIs', 'and p-values.', '47', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}